These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18714569)

  • 21. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
    Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CLIC1 a novel biomarker of intraperitoneal metastasis in serous epithelial ovarian cancer.
    Ye Y; Yin M; Huang B; Wang Y; Li X; Lou G
    Tumour Biol; 2015 Jun; 36(6):4175-9. PubMed ID: 25582317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.
    Bauerschlag D; Bräutigam K; Moll R; Sehouli J; Mustea A; Salehin D; Krajewska M; Reed JC; Maass N; Hampton GM; Meinhold-Heerlein I
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):347-55. PubMed ID: 23090696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.
    Jazaeri AA; Awtrey CS; Chandramouli GV; Chuang YE; Khan J; Sotiriou C; Aprelikova O; Yee CJ; Zorn KK; Birrer MJ; Barrett JC; Boyd J
    Clin Cancer Res; 2005 Sep; 11(17):6300-10. PubMed ID: 16144934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
    Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
    Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and prognostic significance of lost or decreased PDCD5 expression in human epithelial ovarian carcinomas.
    Zhang X; Wang X; Song X; Wei Z; Zhou C; Zhu F; Wang Q; Ma C; Zhang L
    Oncol Rep; 2011 Feb; 25(2):353-8. PubMed ID: 21165576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene microarray analysis of lncRNA and mRNA expression profiles in patients with high‑grade ovarian serous cancer.
    Lou Y; Jiang H; Cui Z; Wang X; Wang L; Han Y
    Int J Mol Med; 2018 Jul; 42(1):91-104. PubMed ID: 29577163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TERT promoter methylation and protein expression as predictive biomarkers for recurrence risk in patients with serous borderline ovarian tumours.
    Losi L; Botticelli L; Garagnani L; Fabbiani L; Panini R; Gallo G; Sabbatini R; Maiorana A; Benhattar J
    Pathology; 2021 Feb; 53(2):187-192. PubMed ID: 33032810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
    Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
    BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion.
    Wang S; Zhang S
    Clin Exp Metastasis; 2011 Aug; 28(6):581-91. PubMed ID: 21607803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
    Chien J; Fan JB; Bell DA; April C; Klotzle B; Ota T; Lingle WL; Gonzalez Bosquet J; Shridhar V; Hartmann LC
    Gynecol Oncol; 2009 Jul; 114(1):3-11. PubMed ID: 19410283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MicroRNA expression profiles in serous ovarian carcinoma.
    Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
    Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Classification of ovarian carcinomas based on pathology and molecular genetics.
    D'Angelo E; Prat J
    Clin Transl Oncol; 2010 Dec; 12(12):783-7. PubMed ID: 21156408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.
    Yan H; Qiu L; Xie X; Yang H; Liu Y; Lin X; Huang H
    Oncol Rep; 2017 Mar; 37(3):1412-1418. PubMed ID: 28184931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
    Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
    Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A distinctive ovarian cancer molecular subgroup characterized by poor prognosis and somatic focal copy number amplifications at chromosome 19.
    Sung CO; Song IH; Sohn I
    Gynecol Oncol; 2014 Feb; 132(2):343-50. PubMed ID: 24321399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
    Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
    BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.